Nifedipine Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL NIFEDIPINE INDUSTRY

2.1 Summary about Nifedipine Industry

2.2 Nifedipine Market Trends

2.2.1 Nifedipine Production & Consumption Trends

2.2.2 Nifedipine Demand Structure Trends

2.3 Nifedipine Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Nifedipine Controlled Release Tablets

4.2.2 Nifedipine Extended Action Tablets

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Primary Pulmonary Hypertension

4.3.2 Heart Failure

4.3.3 Raynaud's Syndrome

4.3.4 Cephalagra

4.3.5 Bronchial Asthma

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Nifedipine Controlled Release Tablets

5.2.2 Nifedipine Extended Action Tablets

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Primary Pulmonary Hypertension

5.3.2 Heart Failure

5.3.3 Raynaud's Syndrome

5.3.4 Cephalagra

5.3.5 Bronchial Asthma

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Nifedipine Controlled Release Tablets

6.2.2 Nifedipine Extended Action Tablets

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Primary Pulmonary Hypertension

6.3.2 Heart Failure

6.3.3 Raynaud's Syndrome

6.3.4 Cephalagra

6.3.5 Bronchial Asthma

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Nifedipine Controlled Release Tablets

7.2.2 Nifedipine Extended Action Tablets

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Primary Pulmonary Hypertension

7.3.2 Heart Failure

7.3.3 Raynaud's Syndrome

7.3.4 Cephalagra

7.3.5 Bronchial Asthma

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Nifedipine Controlled Release Tablets

8.2.2 Nifedipine Extended Action Tablets

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Primary Pulmonary Hypertension

8.3.2 Heart Failure

8.3.3 Raynaud's Syndrome

8.3.4 Cephalagra

8.3.5 Bronchial Asthma

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Nifedipine Controlled Release Tablets

9.2.2 Nifedipine Extended Action Tablets

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Primary Pulmonary Hypertension

9.3.2 Heart Failure

9.3.3 Raynaud's Syndrome

9.3.4 Cephalagra

9.3.5 Bronchial Asthma

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Bayer

10.1.2 Actavis

10.1.3 Teva

10.1.4 Pfizer

10.1.5 Shyndec

10.1.6 Honglin

10.1.7 Huanghai

10.1.8 Yabao

10.1.9 Global Pharm

10.1.10 Huazhon

10.2 Nifedipine Sales Date of Major Players (2017-2020e)

10.2.1 Bayer

10.2.2 Actavis

10.2.3 Teva

10.2.4 Pfizer

10.2.5 Shyndec

10.2.6 Honglin

10.2.7 Huanghai

10.2.8 Yabao

10.2.9 Global Pharm

10.2.10 Huazhon

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

Table Nifedipine Product Type Overview

Table Nifedipine Product Type Market Share List

Table Nifedipine Product Type of Major Players

Table Brief Introduction of Bayer

Table Brief Introduction of Actavis

Table Brief Introduction of Teva

Table Brief Introduction of Pfizer

Table Brief Introduction of Shyndec

Table Brief Introduction of Honglin

Table Brief Introduction of Huanghai

Table Brief Introduction of Yabao

Table Brief Introduction of Global Pharm

Table Brief Introduction of Huazhon

Table Products & Services of Bayer

Table Products & Services of Actavis

Table Products & Services of Teva

Table Products & Services of Pfizer

Table Products & Services of Shyndec

Table Products & Services of Honglin

Table Products & Services of Huanghai

Table Products & Services of Yabao

Table Products & Services of Global Pharm

Table Products & Services of Huazhon

Table Market Distribution of Major Players

Table Global Major Players Sales Revenue (Million USD) 2017-2020e

Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

Table Global Nifedipine Market Forecast (Million USD) by Region 2021f-2026f

Table Global Nifedipine Market Forecast (Million USD) Share by Region 2021f-2026f

Table Global Nifedipine Market Forecast (Million USD) by Demand 2021f-2026f

Table Global Nifedipine Market Forecast (Million USD) Share by Demand 2021f-2026f